WO2015181624A3 - Nucleoside derivatives for the treatment of cancer - Google Patents
Nucleoside derivatives for the treatment of cancer Download PDFInfo
- Publication number
- WO2015181624A3 WO2015181624A3 PCT/IB2015/000957 IB2015000957W WO2015181624A3 WO 2015181624 A3 WO2015181624 A3 WO 2015181624A3 IB 2015000957 W IB2015000957 W IB 2015000957W WO 2015181624 A3 WO2015181624 A3 WO 2015181624A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- treatment
- nucleoside derivatives
- compositions
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016569379A JP2017516779A (en) | 2014-05-28 | 2015-05-27 | Nucleoside derivatives for cancer treatment |
EP15770630.0A EP3149017B1 (en) | 2014-05-28 | 2015-05-27 | Nucleoside derivatives for the treatment of cancer |
RU2016149761A RU2016149761A (en) | 2014-05-28 | 2015-05-27 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASE |
US15/313,646 US20170101431A1 (en) | 2014-05-28 | 2015-05-27 | Nucleoside derivatives for the treatment of cancer |
CN201580028114.XA CN106459127A (en) | 2014-05-28 | 2015-05-27 | Nucleoside derivatives for the treatment of cancer |
AU2015265607A AU2015265607A1 (en) | 2014-05-28 | 2015-05-27 | Nucleoside derivatives for the treatment of cancer |
CA2947939A CA2947939A1 (en) | 2014-05-28 | 2015-05-27 | Nucleoside derivatives for the treatment of cancer |
KR1020167036090A KR20170005492A (en) | 2014-05-28 | 2015-05-27 | Nucleoside derivatives for the treatment of cancer |
MX2016015568A MX2016015568A (en) | 2014-05-28 | 2015-05-27 | Nucleoside derivatives for the treatment of cancer. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462004006P | 2014-05-28 | 2014-05-28 | |
US62/004,006 | 2014-05-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015181624A2 WO2015181624A2 (en) | 2015-12-03 |
WO2015181624A3 true WO2015181624A3 (en) | 2016-03-31 |
Family
ID=54196997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2015/000957 WO2015181624A2 (en) | 2014-05-28 | 2015-05-27 | Nucleoside derivatives for the treatment of cancer |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP2017516779A (en) |
KR (1) | KR20170005492A (en) |
AU (1) | AU2015265607A1 (en) |
CA (1) | CA2947939A1 (en) |
WO (1) | WO2015181624A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3303359A1 (en) | 2015-05-27 | 2018-04-11 | Idenix Pharmaceuticals LLC | Nucleotides for the treatment of cancer |
GB201609601D0 (en) * | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
GB201609600D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
KR20190065139A (en) * | 2017-12-01 | 2019-06-11 | 압타바이오 주식회사 | Therapeutics of blood cancer |
WO2022245584A1 (en) * | 2021-05-17 | 2022-11-24 | Ligand Pharmaceuticals Incorporated | Unnatural configuration nucleotide prodrug compounds |
WO2023081105A1 (en) * | 2021-11-02 | 2023-05-11 | Ligand Pharmaceuticals Incorporated | Cyclic phosphoramidate compounds |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3804827A (en) * | 1972-02-28 | 1974-04-16 | Icn Pharmaceuticals | 1-beta-d-arabinofuranosylcytosine-3',5'-cyclic phosphate and derivatives thereof |
WO1999045935A1 (en) * | 1998-03-11 | 1999-09-16 | Lipitek International, Inc. | Novel nucleoside analogs and uses in treating disease |
WO2006100439A1 (en) * | 2005-03-21 | 2006-09-28 | University College Cardiff Consultants Limited | Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer |
US20080261913A1 (en) * | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
US20080292553A1 (en) * | 2005-11-09 | 2008-11-27 | Shields Anthony F | Phosphoramidate Derivatives of Fau |
WO2012117246A1 (en) * | 2011-03-01 | 2012-09-07 | Nucana Biomed Limited | Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer |
US20130210757A1 (en) * | 2011-01-03 | 2013-08-15 | Nanjing Molecular Research, Inc. | Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs |
US20130315866A1 (en) * | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
KR890002631B1 (en) | 1984-10-04 | 1989-07-21 | 몬산토 캄파니 | Composition of prolonged release of biologically active somatotropin |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (en) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS. |
PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
WO1994006802A1 (en) | 1992-09-18 | 1994-03-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienodiazepine compound and medicinal use thereof |
TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
IT1270594B (en) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN |
DE69632684T2 (en) | 1995-06-27 | 2005-06-09 | Takeda Pharmaceutical Co. Ltd. | PROCESS FOR PREPARING PREPARED DELETION PREPARATIONS |
TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
JP2909418B2 (en) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | Delayed release microsphere of drug |
US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
ATE272394T1 (en) | 1996-10-31 | 2004-08-15 | Takeda Chemical Industries Ltd | DELAYED RELEASE PREPARATION |
DE69719367T2 (en) | 1996-12-20 | 2003-10-16 | Takeda Chemical Industries, Ltd. | METHOD FOR PRODUCING A COMPOSITION WITH DELAYED DELIVERY |
US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
KR19990085365A (en) | 1998-05-16 | 1999-12-06 | 허영섭 | Biodegradable polymer microspheres capable of continuously controlled controlled release and preparation method thereof |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
PE20010306A1 (en) | 1999-07-02 | 2001-03-29 | Agouron Pharma | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE |
GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
CA2437898A1 (en) | 2001-02-26 | 2002-09-06 | Pharma Pacific Pty. Ltd | Interferon-alpha induced gene |
WO2004004771A1 (en) | 2002-07-03 | 2004-01-15 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions |
US7521051B2 (en) | 2002-12-23 | 2009-04-21 | Medimmune Limited | Methods of upmodulating adaptive immune response using anti-PD-1 antibodies |
US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
BRPI0610235B8 (en) | 2005-05-09 | 2021-05-25 | Squibb & Sons Llc | genetically modified monoclonal antibodies different from those found in nature, or antigen-binding portion thereof, therapeutic uses thereof, compositions, immunoconjugate, bispecific molecule comprising them, nucleic acid molecule and expression vector |
UA99701C2 (en) | 2005-07-01 | 2012-09-25 | Медарекс, Инк. | Human monoclonal antibody that specifically binds to programmed death ligand 1 (pd-l1) |
CA2691357C (en) | 2007-06-18 | 2014-09-23 | N.V. Organon | Antibodies to human programmed death receptor pd-1 |
CN101910182B (en) | 2007-12-28 | 2013-07-17 | 田边三菱制药株式会社 | Antitumor agent |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Pd-1 binding proteins |
JP2012510429A (en) | 2008-08-25 | 2012-05-10 | アンプリミューン、インコーポレーテッド | PD-1 antagonist and method of use thereof |
EP3133086B1 (en) | 2008-09-26 | 2018-08-01 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof |
EP4169951A1 (en) | 2008-12-09 | 2023-04-26 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
TW201840336A (en) | 2011-08-01 | 2018-11-16 | 美商建南德克公司 | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
-
2015
- 2015-05-27 KR KR1020167036090A patent/KR20170005492A/en unknown
- 2015-05-27 JP JP2016569379A patent/JP2017516779A/en not_active Withdrawn
- 2015-05-27 AU AU2015265607A patent/AU2015265607A1/en not_active Abandoned
- 2015-05-27 CA CA2947939A patent/CA2947939A1/en not_active Abandoned
- 2015-05-27 WO PCT/IB2015/000957 patent/WO2015181624A2/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3804827A (en) * | 1972-02-28 | 1974-04-16 | Icn Pharmaceuticals | 1-beta-d-arabinofuranosylcytosine-3',5'-cyclic phosphate and derivatives thereof |
WO1999045935A1 (en) * | 1998-03-11 | 1999-09-16 | Lipitek International, Inc. | Novel nucleoside analogs and uses in treating disease |
WO2006100439A1 (en) * | 2005-03-21 | 2006-09-28 | University College Cardiff Consultants Limited | Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer |
US20080292553A1 (en) * | 2005-11-09 | 2008-11-27 | Shields Anthony F | Phosphoramidate Derivatives of Fau |
US20080261913A1 (en) * | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
US20130210757A1 (en) * | 2011-01-03 | 2013-08-15 | Nanjing Molecular Research, Inc. | Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs |
WO2012117246A1 (en) * | 2011-03-01 | 2012-09-07 | Nucana Biomed Limited | Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer |
US20130315866A1 (en) * | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
Non-Patent Citations (9)
Title |
---|
BAZZANINI ET AL.: "PRODRUGS OF ARA-CMP AND ARA-AMP WITH A S-ACYL-2-THIOETHYL (SATE) BIOLABILE PHOSPHATE PROTECTING GROUP: SYNTHESIS AND BIOLOGICAL EVALUATION", NUCLEOSIDES & NUCLEOTIDES, vol. 18, no. 4/05, 1 January 1999 (1999-01-01), pages 971/972, XP009029311, ISSN: 0732-8311 * |
BAZZANINI ET AL.: "Synthetic approaches to a mononucleotide prodrug of cytarabine", NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS, vol. 24, no. 10-12, 2005, pages 1635 - 1643, XP008141704, ISSN: 1525-7770, [retrieved on 20060816], DOI: 10.1080/15257770500267006 * |
DRUMMOND ET AL.: "Deoxyribonucleoside-3',5' Cyclic Phosphates. Synthesis and Acid-Catalyzed and Enzymic Hydrolysis", J. AM. CHEM. SOC., vol. 86, no. 8, 1 April 1964 (1964-04-01), US, pages 1626 - 1630, XP055221899, ISSN: 0002-7863, DOI: 10.1021/ja01062a036 * |
GOUY ET AL.: "Special feature of mixed phosphotriester derivatives of cytarabine", BIOORG. MED. CHEM., vol. 17, no. 17, 1 September 2009 (2009-09-01), pages 6340 - 6347, XP026471113, ISSN: 0968-0896, [retrieved on 20090723], DOI: 10.1016/J.BMC.2009.07.038 * |
JORDHEIM ET AL.: "Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases", NATURE REVIEWS. DRUG DISCOVERY, vol. 12, no. 6, 31 May 2013 (2013-05-31), GB, pages 447 - 464, XP055221647, ISSN: 1474-1776, DOI: 10.1038/nrd4010 * |
LONG ET AL.: "Synthesis and antitumor antiviral activities of 1-.beta.-D-arabinofuranosylpyrimidine 3',5'-cyclic phosphates", J. MED. CHEM., vol. 15, no. 12, 1 December 1972 (1972-12-01), US, pages 1215 - 1218, XP055221902, ISSN: 0022-2623, DOI: 10.1021/jm00282a003 * |
ROBAK ET AL.: "Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases", MOLECULES, vol. 14, no. 3, 23 March 2009 (2009-03-23), pages 1183 - 1226, XP002583109, ISSN: 1420-3049, [retrieved on 20090101], DOI: 10.3390/MOLECULES14031183 * |
SYMONS ET AL.: "Improved synthesis of <32>P-labelled 3',5'-cyclic AMP, 3',5'-cyclic GMP and other 3',5'cyclic ribo- and deoxyribonucletodies of high specific activity", BIOCHIMICA ET BIOPHYSICA ACTA (BBA), vol. 320, no. 2, 14 September 1973 (1973-09-14), pages 535 - 539, XP025789832, ISSN: 0304-4165, [retrieved on 19730914], DOI: 10.1016/0304-4165(73)90334-6 * |
TOBIAS; BORCH: "Synthesis and Biological Evaluation of a Cytarabine Phosphoramidate Prodrug", MOLECULAR PHARMACEUTICS, vol. 1, no. 2, 2004, pages 112 - 116, XP009186775, DOI: 10.1021/mp034019v * |
Also Published As
Publication number | Publication date |
---|---|
CA2947939A1 (en) | 2015-12-03 |
JP2017516779A (en) | 2017-06-22 |
KR20170005492A (en) | 2017-01-13 |
WO2015181624A2 (en) | 2015-12-03 |
AU2015265607A1 (en) | 2016-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI3640251T1 (en) | 6,7,8,9-tetrahydro-3h-pyrazolo(4,3-f)isoquinoline derivatives useful in the treatment of cancer | |
EP3439653A4 (en) | Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors | |
HK1256283A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
IL258246B (en) | Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer | |
EP3297637A4 (en) | Benzene-1,3,5-tricarboxamide derivatives and uses thereof | |
ZA201807810B (en) | Adenosine derivatives for use in the treatment of cancer | |
WO2015168019A3 (en) | Anti-ptk7 antibody-drug conjugates | |
WO2015181624A3 (en) | Nucleoside derivatives for the treatment of cancer | |
EP3212658A4 (en) | 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer | |
MX2016015568A (en) | Nucleoside derivatives for the treatment of cancer. | |
PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
EP3331542A4 (en) | Compositions and methods for treating cancers associated with etbr activation | |
EP3148526A4 (en) | Use of eribulin in the treatment of cancer | |
MX2017002489A (en) | Human therapeutic agents. | |
EP3166616A4 (en) | Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment | |
MX2019005349A (en) | Use of sanglifehrin macrocyclic analogues as anticancer compounds. | |
EP3242688A4 (en) | Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers | |
IL248773B (en) | 1,6-naphthyridine-4,5-dione derivatives and pharmaceutical compositions comprising them | |
EP3483166A4 (en) | Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same | |
WO2016130581A3 (en) | Combination cancer therapy | |
EP3413906A4 (en) | Cancer treatment combination compositions, methods and uses | |
TW201713323A (en) | Therapeutic compositions and methods of use thereof | |
EP3122381A4 (en) | Use of activin receptor-like kinase 1 (alk-1) antagonists in the treatment of cancer | |
PH12016501434A1 (en) | Compositions for use in the treatment of allergic conditions | |
EP3615020A4 (en) | Methods, agents, and compositions for the treatment of acute myeloid leukemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15770630 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2947939 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2015265607 Country of ref document: AU Date of ref document: 20150527 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15313646 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2016569379 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/015568 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016027574 Country of ref document: BR |
|
REEP | Request for entry into the european phase |
Ref document number: 2015770630 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015770630 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20167036090 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2016149761 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112016027574 Country of ref document: BR Kind code of ref document: A2 Effective date: 20161124 |